Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
AssigneeBoehringer Ingelheim International GmbH
InventorsThomas FRIEDL, Michael BRAUN, Kenji EGUSA, Hikaru FUJITA, Megumi MARUYAMA, Takaaki NISHIOKA
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Claims24
A pharmaceutical composition comprising or made from a DPP-4 inhibitor, a partner drug, and one or more pharmaceutical excipients, and a nucleophilic and/or basic agent for stabilizing said DPP-4 inhibitor against degradation.
A solid pharmaceutical composition comprising or made from
- 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine,
- metformin hydrochloride,
- L-arginine,
- and one or more fillers, one or more binders, one or more glidants and/or one or more lubricants;
- optionally wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine has a particle size distribution of X90<200 μm.
Granules comprising a DPP-4 inhibitor which has a free or primary amino group, metformin hydrochloride, L-arginine, a binder and a filler;
- optionally said granules prepared by fluid bed granulation.
Dependencies are inferred from the claim text.